Vadivarhe Speciality Chemicals Ltd
Chemicals & Petrochemicals | Small Cap
Vadivarhe Speciality Chemicals Ltd, a company in the chemical and petrochemicals sector, exhibits a mixed financial performance. The company shows very strong solvency, suggesting it relies primarily on equity rather than debt for funding. However, its liquidity, growth, coverage, and profitability all appear weak, indicating potential challenges in meeting short-term obligations, expanding operations, and generating profit. On the positive side, the company's capital expenditures are well-managed. Areas of concern include negative interest coverage and inconsistent earnings, which could pose risks for investors. Overall, the company's financial health requires close monitoring due to its volatile performance and areas of significant weakness, despite its strong solvency position.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsHighly Undervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio2.00
- Financial Ratio4.00
- Profitability Ratio2.00
- Efficiency Ratio4.67
- Coverage Ratio2.00
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentWeak
- Risk AssessmentWeak
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Vadivarhe Speciality Chemicals Ltd, a company in the chemical and petrochemicals sector, exhibits a mixed financial performance. The company shows very strong solvency, suggesting it relies primarily on equity rather than debt for funding. However, its liquidity, growth, coverage, and profitability all appear weak, indicating potential challenges in meeting short-term obligations, expanding operations, and generating profit. On the positive side, the company's capital expenditures are well-managed. Areas of concern include negative interest coverage and inconsistent earnings, which could pose risks for investors. Overall, the company's financial health requires close monitoring due to its volatile performance and areas of significant weakness, despite its strong solvency position.
Overall Valuation Score
P/E RATIO (TTM)
-3.66
Industry Median
22.59
Small Cap Median
21.70
P/E RATIO
-3.66
P/B RATIO
-5.11
Industry Median
1.76
Small Cap Median
1.77
P/S RATIO
0.89
Industry Median
0.89
Small Cap Median
0.88
Others
PEG RATIO
-2.40
EV/EBITDA RATIO
-9.38
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹26.5 as on Jun 10, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
All growth metrics, including revenue growth, operating profit growth, EPS growth, asset growth, and net income growth, are at very low levels. This indicates significant challenges in expanding operations and increasing profitability. The company needs to identify and address the factors hindering its growth to ensure long-term sustainability. Without growth, the company may struggle to remain competitive in the market.
| Growth Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -7.38 | -18.96 | 103.64 | -8.24 | -5.41 |
| Operating Profit Growth Rate | -94.16 | 1157.41 | -150.96 | 32.95 | -228.04 |
| Earnings Per Share (EPS) Growth | -71.95 | 248.15 | -111.97 | -94.44 | -14600 |
| Asset Growth Rate | -11.68 | 11.45 | -10.4 | 2.69 | |
| Net Income Growth Rate | -71.95 | 248.19 | -111.97 | -94.78 | -15550 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present a mixed picture. While capital expenditures are well-managed, adjusted EPS and book value per share are minimal, and the dividend per share is also low. The cash EPS is slightly better. Enhancing earnings and optimizing capital allocation are crucial for improving overall financial performance. The company needs to focus on strategies to improve shareholder value.
| Financial Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | -2.74 | -7.7 | 0.62 | 0.06 | -7.18 |
| Cash Earnings Per Share (Cash EPS) | -0.74 | -6.11 | 2.3 | 1.41 | -5.8 |
| Book Value Per Share | 11.63 | 4.12 | 5.02 | 5.07 | -2.17 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 0.1 | 0.9 | 0.8 | 0.5 | 1.3 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios are low across the board, with minimal gross profit margin, ROCE, ROE, ROA, operating margin, and net margin. This indicates significant challenges in generating profits from its operations. Improving cost management, enhancing operational efficiency, and increasing sales are crucial for enhancing profitability. The company needs to focus on strategies to improve its profit margins.
| Profitability Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Gross Profit Margin | -8.88 | -40 | 3.82 | 7.14 | -20.42 |
| Return on Capital Employed (ROCE) | -5.34 | -24.02 | 7.61 | 10.15 | -22.66 |
| Return on Equity (ROE) | -18.54 | -182.01 | 17.91 | 0.92 | |
| Return on Assets (ROA) | -1.14 | -16.29 | 7.45 | 11.06 | -13.78 |
| Operating Margin | -2.04 | -31.66 | 7.92 | 11.48 | -15.54 |
| Net Margin | -10.43 | -44.8 | 2.63 | 0.15 | -24.45 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios are somewhat mixed. While days sales in inventory and receivable days are very high, indicating efficient handling of inventory and receivables, the fixed asset, inventory, receivables, and capital turnover ratios are minimal. This suggests potential inefficiencies in utilizing assets to generate revenue, which may hinder overall performance. Improving asset utilization could significantly enhance the company's operational efficiency.
| Efficiency Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.02 | 0.88 | 1.87 | 1.86 | 1.69 |
| Inventory Turnover Ratio | 8.63 | 5.91 | 5.46 | 4.34 | 4.99 |
| Receivables Turnover Ratio | 2.91 | 3.85 | 11.21 | 7.48 | 5.74 |
| Days Sales in Inventory Ratio | 42.29 | 61.76 | 66.85 | 84.1 | 73.15 |
| Receivable Days | 125.62 | 94.81 | 32.56 | 48.8 | 63.59 |
| Capital Turnover Ratio | 0.79 | 1.01 | 1.93 | 1.58 | 1.89 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios are low, with a negative interest coverage ratio and a minimal equity dividend coverage ratio. This indicates potential challenges in meeting its interest obligations and providing dividends to shareholders. Improving earnings and reducing debt are crucial for enhancing coverage ratios and ensuring financial stability. The company needs to prioritize improving its financial health to meet its financial obligations.
| Coverage Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | -0.96 | -4.69 | 1.71 | 1.82 | -4.39 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits a very strong solvency position, primarily funded by equity, with minimal reliance on debt. This indicates a stable financial structure and a low risk of financial distress due to debt obligations. The high equity ratio suggests that the company has a substantial cushion to absorb potential losses. This is a significant strength, providing a solid foundation for future growth and stability.
| Solvency Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debt Ratio | 0.56 | 0.75 | 0.72 | 0.74 | 1.14 |
| Debt to Equity Ratio | 1.27 | 3 | 2.57 | 2.85 | -8.14 |
| Equity Ratio | 0.44 | 0.25 | 0.28 | 0.26 | -0.14 |
| Debt To Asset Ratio | 0.4 | 0.38 | 0.35 | 0.45 | 0.53 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is concerning. All liquidity ratios, including the current ratio, quick ratio, cash ratio, and operating cash flow ratio, are at minimal levels. This suggests the company may struggle to meet its short-term obligations. Low liquidity can restrict operational flexibility and increase financial risk, particularly in unexpected economic downturns. This is a critical area that needs immediate attention to ensure the company's ability to handle its day-to-day financial needs.
| Liquidity Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Current Ratio | 1.54 | 0.79 | 0.93 | 1.13 | 0.89 |
| Quick Ratio | 1.29 | 0.46 | 0.57 | 0.6 | 0.46 |
| Cash Ratio | 0.07 | 0.04 | 0.03 | 0.03 | 0.03 |
| Operating Cash Flow Ratio | -0.02 | 0.06 | -0.01 | 0.14 | -0.32 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Saroja Pharma Industries India Ltd | 7.47 | 13.67 | Neutral | 3.81 | 4.02 | 1.62 |
| 2 | Sanginita Chemicals Ltd | 7.17 | 62.58 | Undervalued | -6.00 | -3.74 | -10.00 |
| 3 | Yasons Chemex Care Ltd | 5.91 | 22.35 | Neutral | -0.59 | 0.49 | 0.94 |
| 4 | Vadivarhe Speciality Chemicals Ltd | 4.07 | -3.66 | Highly Undervalued | -6.42 | -7.25 | -9.27 |
The management effectiveness of Vadivarhe Speciality Chemicals Ltd is weak. The company exhibits inconsistent financial performance, marked by fluctuating sales and net losses. Declining profitability and negative returns on equity raise concerns about the efficient use of shareholder funds. While promoter holding remains relatively high, recent decreases could signal a lack of confidence. Overall, financial instability and negative performance indicators suggest significant challenges in management effectiveness.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 66.83% | Demonstrates continued alignment with company's performance. |
| CONS | Net Profit | Negative | Shows periods of losses instead of profit. |
| Return on Equity (ROE) | -503% | Indicates poor returns from shareholder funds. | |
| Operating Profit Margin (OPM) | -16.93% | Reflects operational inefficiency. |
Financial Performance & Growth
Vadivarhe Speciality Chemicals demonstrates poor financial performance and inconsistent growth. The compounded sales growth shows a declining trend, with the latest TTM at -5%. Profit growth is significantly negative, with a TTM of -11763%. The operating profit margin (OPM) is also concerning, fluctuating between positive and negative values, with a recent negative OPM of -16.93% in Mar 2025. Net profit shows a similar inconsistent pattern, with significant losses reported in recent periods.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Compounded Sales Growth (%) | N/A | N/A | N/A | 21% | N/A | N/A |
| Compounded Profit Growth (%) | N/A | N/A | N/A | 2% | N/A | N/A |
Capital Efficiency & Returns
Capital efficiency and returns for Vadivarhe Speciality Chemicals are weak. The Return on Capital Employed (ROCE) and Return on Equity (ROE) are negative, indicating poor utilization of capital and shareholder funds. Specifically, the ROCE% is -24.27% as of Mar 2025. The ROE also shows negative returns, with a 10-year average of -13%, a 5-year average of -54%, and a last-year value of -503%. These negative returns raise significant concerns about the company's ability to generate profits from its capital base.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROCE (%) | 17.5% | 13.5% | -11.5% | 7.61% | 10.15% | -24.27% |
| ROE (%) | N/A | N/A | N/A | N/A | N/A | -503% |
Financial Health & Prudence
Vadivarhe Speciality Chemicals exhibits average financial health with some areas of concern. Borrowings increased from 26.18 Cr in Mar 2024 to 36.03 Cr in Mar 2025.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Borrowings (Cr) | 12.41 | 14.13 | 20.85 | 26.94 | 26.18 | 36.03 |
Shareholding & Ownership Structure
The shareholding and ownership structure of Vadivarhe Speciality Chemicals shows a moderate level of promoter confidence, which is decreasing. The promoter holding has decreased from 74.64% consistently until Mar 2024 to 66.83% in Mar 2025. This decrease could indicate a shift in confidence or strategic decisions by the promoters.
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding (%) | 73.56 | 74.62 | 74.62 | 74.62 | 74.64 | 74.64 | 74.64 | 66.83 |
The risk assessment for Vadivarhe Speciality Chemicals is high. The company's negative profitability, operational inefficiencies, and decreasing promoter holding collectively contribute to a high-risk profile. The recent increase in borrowings and negative cash flows from operating activities further exacerbate the financial strain. The company's volatile financial performance and negative returns underscore the significant challenges it faces in achieving sustainable profitability and operational stability.
Off-balance sheet exposure quantification
There is no specific data available on off-balance sheet exposures.
Contingent liability evaluation
There is no specific data available on contingent liabilities.
Accounting quality red flags
There is no specific data available on accounting quality red flags.
Foreign exchange or interest rate exposure
There is no specific data available on foreign exchange or interest rate exposure.
Regulatory compliance cost trends
There is no specific data available on regulatory compliance cost trends.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe